Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PMCB Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
SILVER SPRING, Md., Feb. 10, 2016 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on the report saying, “In our opinion the Research Report released by Stonegate Capital Partners and authored by Senior Research Analyst Laura S. Engel is comprehensive and captures the essence of what we are trying to accomplish at PharmaCyte. Particular emphasis is placed on the two major programs underway that employ our proprietary Cell-in-a-Box® live-cell encapsulation technology to tackle two of the most difficult to treat diseases in the world - cancer and diabetes.”
Stonegate’s Senior Research Analyst, Laura S. Engel, authored the Research Report, which focuses on PharmaCyte’s clinical development of a variety of potential therapies across several areas of disease utilizing its novel live cell encapsulation platform, Cell-in-a-Box®.
Stonegate’s Senior Research Analyst writes that PharmaCyte offers a significant opportunity for investors looking to participate in this development. “We believe that PMCB has a solid pathway towards commercialization with the approach outlined for its Phase 2b study for pancreatic cancer patients set to begin in the Q2-Q3 of calendar year 2016. Additionally, management will be actively moving other potential treatments along; these treatments are related to malignant ascites fluid accumulation in the abdomens of patients with abdominal cancers and Type 1 and Type 2 diabetes. Positive news flow should yield investor returns as the Company accomplishes its milestones that have been set for 2016.”
Senior Research Analyst Laura S. Engel started a career in public accounting following graduation from the University of Virginia, McIntire School of Business, with a B.S. in Accounting. After several years with Arthur Andersen, Engel transitioned in industry where she worked for several publicly traded companies, managing both domestic and international accounting operations. Engel subsequently transitioned into the finance realm, joining a Financial Services consulting team with KPMG Consulting focusing on systems implementations for several Wall Street banks. She later joined a smaller wealth management group, servicing a book of clientele through investment management and financial planning. Since 2003, Engel has teamed with Stonegate and worked in several areas of the business.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (prodrug) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com
http://www.econotimes.com/Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
$PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
http://www.econotimes.com/Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
## source: finance.yahoo.com
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $49,479,488 a/o Feb 10, 2016
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
$PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
http://www.econotimes.com/Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
## source: finance.yahoo.com
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $49,479,488 a/o Feb 10, 2016
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
$PMCB correction.....Lots of excitement at the moment about the use of encapsulated insulin producing cells like we are co-developing with publications in Nature and Nature Biotechnology as well as the recent news that ViaCyte has teamed up with Johnson & Johnson
$PMCB our subsidiary ViaCyte Team Up With Johnson & Johnson
Johnson & Johnson, ViaCyte testing possible diabetes cure
LINDA A. JOHNSON, Associated Press
Published: February 4, 2016, 9:00 am
Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) 2K+Share on Facebook (Opens in new window)2K+ Click to share on Pinterest (Opens in new window)
This photo provided by ViaCyte shows the Encaptra delivery system, placed next to a quarter to give a size perspective.
This photo provided by ViaCyte shows the Encaptra delivery system, placed next to a quarter to give a size perspective.
UNDATED (AP) — Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder.
They’ve already begun testing it in a small number of diabetic patients. If it works as well in patients as it has in animals, it would amount to a cure, ending the need for frequent insulin injections and blood sugar testing.
ViaCyte and Johnson & Johnson’s Janssen BetaLogics group said Thursday they’ve agreed to combine their knowledge and hundreds of patents on their research under ViaCyte, a longtime J&J partner focused on regenerative medicine.
The therapy involves inducing embryonic stem cells in a lab dish to turn into insulin-producing cells, then putting them inside a small capsule that is implanted under the skin. The capsule protects the cells from the immune system, which otherwise would attack them as invaders — a roadblock that has stymied other research projects.
Researchers at universities and other drug companies also are working toward a diabetes cure, using various strategies. But according to ViaCyte and others, this treatment is the first tested in patients.
If the project succeeds, the product could be available in several years for Type 1 diabetes patients and down the road could also treat insulin-using Type 2 diabetics.
“This one is potentially the real deal,” said Dr. Tom Donner, director of the diabetes center at Johns Hopkins University School of Medicine. “It’s like making a new pancreas that makes all the hormones” needed to control blood sugar.
Donner, who is not involved in the research, said if the device gives patients normal insulin levels, “it’s going to prevent millions of diabetics from getting dangerous complications.”
People with Type 1 diabetes no longer produce insulin, the hormone that converts sugar in the blood into energy, because their immune system has killed off the beta cells in the pancreas. Those cells make insulin in response to rising blood sugar levels after a meal.
Over years, excess sugar in the bloodstream damages blood vessels and organs. Without effective treatment, diabetics suffer severe complications: blindness, kidney failure, heart disease, amputations, even premature death. On the other hand, too much insulin can cause very low blood sugar, which can kill patients, particularly young children.
According to the American Diabetes Association, about 29.1 million Americans have diabetes, including 1.25 million with type 1 diabetes. The number with Type 1, or insulin-dependent, diabetes is growing steadily. Meanwhile, the number with Type 2 diabetes, whose bodies make some insulin but don’t use it efficiently, is increasing exponentially due to the global epidemic of obesity and sedentary lifestyles.
Many patients can’t control it well because treatment is exhausting, requiring a strict diet, frequent exercise, multiple daily insulin injections or other medicines and several finger pricks a day to test blood sugar. Also, some patients can’t afford the expensive medicines.
ViaCyte Inc., based in San Diego, has been researching its treatment for a decade, partly with funding from the Juvenile Diabetes Research Fund and the California Institute for Regenerative Medicine.
Johnson & Johnson, based in New Brunswick, New Jersey, is a major ViaCyte investor and has been conducting parallel research for about 13 years, said Diego Miralles, J&J’s head of global innovation.
“We wanted to hedge our bets to make sure we would win in this space … that is so transformational,” Miralles said.
He wouldn’t disclose financial terms of the deal with ViaCyte.
The privately held company began the first round of patient testing a year ago, implanting its product, dubbed VC-01, in a dozen people with Type 1 diabetes, said Paul Laikind, ViaCyte’s CEO and president. They received a small dose of insulin-producing cells inside their devices and are being closely monitored for two years to see insulin production and other effects.
After 12 weeks, the device had properly attached to nearby blood vessels, their new insulin-producing cells were still multiplying and no side effects were seen. Another dozen planned patients will soon get the same cell dose in capsules to be implanted in them.
If that goes well, in the next round of testing a few dozen patients will get devices holding a full dose of the cells implanted, likely in the second half of this year. Further testing may be needed before the product can be approved by regulators.
“We do believe that it will need to be replaced periodically,” Laikind said.
Earlier testing in thousands of mice over years showed the lab-created insulin-producing cells matured and produced the needed hormone inside the mice for as long as they lived, about a year, noted Laikind.
Because of the protective capsule, which is flattish and smaller than a business card, if something goes awry, the capsule can be removed immediately to prevent patient harm.
Dr. Betul Hatipoglu, an endocrinologist at Cleveland Clinic, wrote in an email that preliminary results on the device are promising.
“More research is needed to continue to understand its impact,” she wrote, adding that researchers must fine tune the device and determine whether there are any unforeseen safety issues.
Share this:
EmailPrintFacebook2K+TwitterGooglePinterestMore
Advertisement
More Headlines
Previous post in this category
In this April 13, 2014 file photo, the Internal Revenue Service Headquarters (IRS) building is seen in Washington. (AP Photo/J. David Ake, File)
IRS halts e-file tax returns after hardware failure
NATIONAL Next post in this category
Pharmaceutical chief Martin Shkreli listens on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. (AP Photo/Susan Walsh)
Lawmakers anxious to hear from Shkreli, but he’s taking 5th
NATIONAL
by Taboola Sponsored Links You May Like
Homeowners Are in for a Big Surprise in 2016
HarpRefiQuotes
The Story Behind Your Last Name Might Surprise You
Ancestry
The Insane Military Issued Flashlight Finally Available To Public
Brightest Tactical Flashlight
http://woodtv.com/2016/02/04/johnson-johnson-viacyte-testing-possible-diabetes-cure/
Nice close
Go $DCAC
$SAKL Sack Lunch Productions to Present at the RedChip Global Online Microcap Conference
SALT LAKE CITY, UT--(Marketwired - Feb 8, 2016) - Sack Lunch Productions, Inc. (OTC PINK: SAKL) (the "Company"), an entertainment company that operates and franchises action oriented events in the U.S. and internationally, is scheduled to present at the RedChip Global Online Microcap Conference on Thursday, February 11, 2016, at 2:00 p.m. Eastern time. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.
The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.
No registration is required to participate in the conference. Start times are subject to change.
Please visit our websites to find the next event in your area: www.slidethecity.com, www.thelanternfest.com, www.thedirtydash.com, and www.colormerad.com.
About Sack Lunch Productions, Inc.
Sack Lunch Productions, Inc. (OTC PINK: SAKL) is an entertainment company that operates and franchises action oriented events in the U.S. and internationally. SAKL's events include: Slide the City (1,000 foot long water slide for families and kids), Color Me Rad (5k color race), The Dirty Dash (mud and obstacle run), and The Lantern Fest (nighttime party with lantern lighting and launch). Learn more about SAKL's operations at www.sacklunchproductions.com, www.slidethecity.com, www.thelanternfest.com, www.thedirtydash.com, www.colormerad.com, and www.green-endeavors.com.
SAKL strongly encourages the public to read the above information in conjunction with its reports filed at www.otcmarkets.com. The actual results that SAKL may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. Investors should not invest more than they can afford to lose.
Contact:
RedChip Companies, LLC
Bruce Haase
407-644-4256 X131
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
$SAKL Sack Lunch Productions to Present at the RedChip Global Online Microcap Conference
SALT LAKE CITY, UT--(Marketwired - Feb 8, 2016) - Sack Lunch Productions, Inc. (OTC PINK: SAKL) (the "Company"), an entertainment company that operates and franchises action oriented events in the U.S. and internationally, is scheduled to present at the RedChip Global Online Microcap Conference on Thursday, February 11, 2016, at 2:00 p.m. Eastern time. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.
The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.
No registration is required to participate in the conference. Start times are subject to change.
Please visit our websites to find the next event in your area: www.slidethecity.com, www.thelanternfest.com, www.thedirtydash.com, and www.colormerad.com.
About Sack Lunch Productions, Inc.
Sack Lunch Productions, Inc. (OTC PINK: SAKL) is an entertainment company that operates and franchises action oriented events in the U.S. and internationally. SAKL's events include: Slide the City (1,000 foot long water slide for families and kids), Color Me Rad (5k color race), The Dirty Dash (mud and obstacle run), and The Lantern Fest (nighttime party with lantern lighting and launch). Learn more about SAKL's operations at www.sacklunchproductions.com, www.slidethecity.com, www.thelanternfest.com, www.thedirtydash.com, www.colormerad.com, and www.green-endeavors.com.
SAKL strongly encourages the public to read the above information in conjunction with its reports filed at www.otcmarkets.com. The actual results that SAKL may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. Investors should not invest more than they can afford to lose.
Contact:
RedChip Companies, LLC
Bruce Haase
407-644-4256 X131
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Haha...I load 1M on the bid at $.0014 but never get fill so I leave it there as the support
Go $SIPC
$TRXC TransEnterix, Inc. to Participate at Two Upcoming Healthcare Conferences
Business Wire TransEnterix, Inc.
4 hours ago
????
Related Quotes
TRXC
4.21
-4.32%
TransEnterix, Inc.? Watchlist
4.21-0.19(4.32%)
AMEXWed, Feb 10, 2016 4:02 PM EST
Here's Why TransEnterix (TRXC) Stock Is Plummeting Today TheStreet q 8 hrs ago
Transenterix Falls 10% Benzinga 11 hrs ago
More
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
TransEnterix, Inc. (NYSE MKT: TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2016 Healthcare Conference at the New York Palace Hotel in New York. The presentation is scheduled to take place at 2:05 pm Eastern Time on Tuesday, February 23, 2016.
To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm.
Joseph P. Slattery, Executive Vice President and Chief Financial Officer, is also scheduled to participate in the BTIG Medtech Conference at the Cliff Lodge in Snowbird, Utah on February 24 - 26, 2016.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160210006594/en/
Contact:
TransEnterix, Inc.
Investor Contact:
Mark Klausner, 443-213-0501
transenterix@westwicke.com
or
Media Contact:
Mohan Nathan, 919-917-6559
mnathan@transenterix.com
$TRXC TransEnterix, Inc. to Participate at Two Upcoming Healthcare Conferences
Business Wire TransEnterix, Inc.
4 hours ago
????
Related Quotes
TRXC
4.21
-4.32%
TransEnterix, Inc.? Watchlist
4.21-0.19(4.32%)
AMEXWed, Feb 10, 2016 4:02 PM EST
Here's Why TransEnterix (TRXC) Stock Is Plummeting Today TheStreet q 8 hrs ago
Transenterix Falls 10% Benzinga 11 hrs ago
More
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
TransEnterix, Inc. (NYSE MKT: TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets 2016 Healthcare Conference at the New York Palace Hotel in New York. The presentation is scheduled to take place at 2:05 pm Eastern Time on Tuesday, February 23, 2016.
To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm.
Joseph P. Slattery, Executive Vice President and Chief Financial Officer, is also scheduled to participate in the BTIG Medtech Conference at the Cliff Lodge in Snowbird, Utah on February 24 - 26, 2016.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160210006594/en/
Contact:
TransEnterix, Inc.
Investor Contact:
Mark Klausner, 443-213-0501
transenterix@westwicke.com
or
Media Contact:
Mohan Nathan, 919-917-6559
mnathan@transenterix.com
Thank you! Hope you are doing well and getting better now
Very nice close today on SIPC
Go $SIPC
Nice close
Go $SIPC
Someone is loading up 3M at $.0022 this morning. Maybe something big is on the way
Go $SIPC
$ADVT is number 3 on BOB. Bring lots of awareness now
Go $ADVT